Free Trial

Molina Healthcare (MOH) Stock Forecast & Price Target

Molina Healthcare logo
$295.12 -5.30 (-1.76%)
(As of 12/6/2024 ET)

Molina Healthcare - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
6
Buy
6

Based on 13 Wall Street analysts who have issued ratings for Molina Healthcare in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 1 has given a sell rating, 6 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for MOH.

Consensus Price Target

$367.17
24.41% Upside
According to the 13 analysts' twelve-month price targets for Molina Healthcare, the average price target is $367.17. The highest price target for MOH is $439.00, while the lowest price target for MOH is $297.00. The average price target represents a forecasted upside of 24.41% from the current price of $295.12.
Get the Latest News and Ratings for MOH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Molina Healthcare and its competitors.

Sign Up

MOH Analyst Ratings Over Time

TypeCurrent Forecast
12/7/23 to 12/6/24
1 Month Ago
11/7/23 to 11/6/24
3 Months Ago
9/8/23 to 9/7/24
1 Year Ago
12/7/22 to 12/7/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$367.17$367.17$378.00$349.82
Forecasted Upside24.41% Upside12.48% Upside15.43% Upside-3.75% Downside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

MOH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MOH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Molina Healthcare Stock vs. The Competition

TypeMolina HealthcareMedical CompaniesS&P 500
Consensus Rating Score
2.46
2.81
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside24.14% Upside26,336.48% Upside8.57% Upside
News Sentiment Rating
Very Positive News

See Recent MOH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/4/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$360.00 ➝ $362.00+10.70%
10/25/2024Barclays
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$359.00 ➝ $372.00+12.74%
10/24/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$406.00 ➝ $406.00+22.41%
10/24/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$405.00 ➝ $331.00+20.48%
7/29/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$354.00 ➝ $353.00+6.02%
7/25/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual Weight ➝ Equal Weight$320.00 ➝ $320.00-1.32%
7/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$354.00 ➝ $297.00+2.86%
7/24/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$412.00 ➝ $351.00+21.57%
7/15/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$440.00 ➝ $400.00+36.52%
7/10/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$420.00 ➝ $395.00+38.68%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/28/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$439.00+4.90%
12/21/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$350.00 ➝ $380.00+7.26%
7/14/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$365.00+21.87%
4/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$347.00 ➝ $350.00+17.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:27 AM ET.


Should I Buy Molina Healthcare Stock? MOH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 1, 2024. Please send any questions or comments about these Molina Healthcare pros and cons to contact@marketbeat.com.

Molina Healthcare
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Molina Healthcare, Inc.:

  • Molina Healthcare, Inc. recently reported earnings of $6.01 per share, exceeding the consensus estimate of $5.96, indicating strong financial performance and effective management.
  • The company has a solid market capitalization of approximately $17.04 billion, reflecting its significant presence in the healthcare sector and potential for growth.
  • With a return on equity of 27.88%, Molina Healthcare, Inc. demonstrates efficient use of shareholders' equity to generate profits, which is attractive to investors seeking high returns.
  • The stock is currently trading at $297.97, showing a recent increase of 2.5%, which may indicate positive market sentiment and potential for further appreciation.
  • Molina Healthcare, Inc. has a relatively low debt-to-equity ratio of 0.53, suggesting a conservative approach to leveraging, which can reduce financial risk for investors.

Molina Healthcare
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Molina Healthcare, Inc. for these reasons:

  • The stock has experienced significant volatility, with a 52-week high of $423.92 and a low of $272.69, indicating potential risks associated with price fluctuations.
  • Molina Healthcare, Inc. has a price-to-earnings (P/E) ratio of 15.12, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • The company's net margin of 2.92% is relatively low, which could indicate challenges in maintaining profitability amidst rising operational costs.
  • Institutional investors hold 98.50% of the stock, which may lead to less liquidity and increased volatility, as large trades can significantly impact the stock price.
  • Recent changes in institutional holdings, such as Thrivent Financial reducing its stake by 4.6%, may signal a lack of confidence among major investors, which could affect market perception.

MOH Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Molina Healthcare is $367.17, with a high forecast of $439.00 and a low forecast of $297.00.

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molina Healthcare in the last twelve months. There is currently 1 sell rating, 6 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOH, but not buy additional shares or sell existing shares.

According to analysts, Molina Healthcare's stock has a predicted upside of 24.41% based on their 12-month stock forecasts.

Molina Healthcare has been rated by research analysts at Barclays, Cantor Fitzgerald, Robert W. Baird, and Wells Fargo & Company in the past 90 days.

Analysts like Molina Healthcare less than other "medical" companies. The consensus rating for Molina Healthcare is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MOH compares to other companies.


This page (NYSE:MOH) was last updated on 12/6/2024 by MarketBeat.com Staff
From Our Partners